Please ensure Javascript is enabled for purposes of website accessibility

Cronos Group Slides 3% on Q1 Results

By Eric Volkman - May 8, 2020 at 4:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Revenue came in under expectations, while there was a large asterisk next to the net profit line item.

Cronos Group (CRON 0.29%) traded lower on Friday in the wake of the Q1 of fiscal 2020 results it published early in the day.

For the quarter, the company posted revenue of $8.43 million, which was 15% higher on a quarter-over-quarter basis and nearly three times the Q1 2019 figure. On the bottom line, net income rose to $75.7 million ($0.20 per diluted share) from the previous quarter's $61.6 million.

Cannabis flower in a bowl atop U.S. currency.

Image source: Getty Images.

On average, analysts estimated Cronos would earn $10.8 million on the top line and post a per-share net profit of only $0.07.

As in previous quarters, however, the company's bottom line was influenced by a large adjustment -- namely, the revaluation of derivative liabilities. This has to do with the value of warrants that Cronos' strategic investor Altria holds in the company, and is essentially an accounting adjustment.

Without Q1's $113 million revaluation, Cronos would have been well in the red on the bottom line. Perhaps a more revealing line item in this respect was the company's operating loss, which came in at just over $45 million for the quarter. That was narrower than the nearly $64 million deficit of Q4 2019 but deeper than the $10.1 million posted in last-year's Q1.

The marijuana company said its revenue got a boost from the rollout of new products, such as vaporizers for the recreational cannabis market in its native Canada. South of that border, Cronos signaled out a new cannabidiol (CBD)-infused moisturizer sold under its U.S. CBD brand, Lord Jones.

Cronos stock fell by 3% Friday on a day when the major stock market indexes all posted gains.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
CRON
$3.41 (0.29%) $0.01
Altria Group, Inc. Stock Quote
Altria Group, Inc.
MO
$45.74 (1.02%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.